恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床疗效分析

Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis

目的探讨恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床疗效和安全性。方法本研究选取2015年2月~2016年7月我院收治的失代偿期乙型肝炎肝硬化初治患者120例,根据入院顺序的单双号分为观察组和对照组,每组60例。两组均给予常规治疗,在此基础上,对照组给予拉米夫定治疗,观察组给予恩替卡韦治疗,50周后,对比两组患者的Child-Pugh积分、血清病毒学HBV-DNA和PTA的数据。结果治疗50周后,两组患者治疗指标均有所好转,观察组Child-Pugh积分、HBVDNA、PTA分别为(9.48±1.87)分、(2.87±0.12)log copies/ml、(0.79±0.11)%,优于对照组的(5.76±1.09)分、(4.58±0.46)log copies/ml、(0.61±0.12)%,差异均具有统计学意义(P<0.05)。结论恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床疗效满意,值得临床推广应用。

Objective To investigate the clinical efficacy and safety of entecavir antiviral therapy in patients with decompensated hepatitis B liver cirrhosis.Methods In this study,120 patients with decompensated hepatitis B cirrhosis who were treated in our hospital from February 2015 to July 2016 were selected and divided into an observation group and a control group according to the odd and even numbers of the admission order.60 cases in each group.Both groups received conventional treatment.On this basis,the control group received lamivudine treatment.The observation group received entecavir treatment.After 50 weeks,the Child-Pugh scores,serum virological HBV-DNA and PTA data were compared between the two groups.Results After 50 weeks of treatment,the treatment indicators of both groups improved.The Child-Pugh score,HBV-DNA,and PTA in the observation group were(9.48±1.87)points,(2.87±0.12)log copies/ml,(0.79±0.11)%,better than the control group(5.76±1.09)points,(4.58±0.46)log copies/ml,(0.61±0.12)%,the difference was statistically significant(P<0.05).Conclusion The clinical efficacy of entecavir antiviral therapy in patients with decompensated hepatitis B cirrhosis is satisfactory and worthy of clinical application.